AbbVie Inc (ABBV)vsSanara Medtech Inc (SMTI)
ABBV
AbbVie Inc
$257.12
+0.83%
HEALTHCARE · Cap: $454.36B
SMTI
Sanara Medtech Inc
$34.92
-0.31%
HEALTHCARE · Cap: $319.10M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 58531% more annual revenue ($64.39B vs $109.81M). ABBV leads profitability with a 9.8% profit margin vs -29.1%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
SMTI
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-69.4%
Fair Value
$151.82
Current Price
$257.12
$105.30 premium
Margin of Safety
+58.6%
Fair Value
$46.87
Current Price
$34.92
$11.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.9% — below average capital efficiency
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : SMTI
SMTI has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : SMTI
The primary concerns for SMTI are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 6.11 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while SMTI is a turnaround play — different risk/reward profiles.
SMTI carries more volatility with a beta of 1.16 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 25/100) and 10.2% revenue growth. SMTI offers better value entry with a 58.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Sanara Medtech Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Sanara MedTech Inc. develops, markets and distributes skin and wound care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company is headquartered in Fort Worth, Texas.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?